These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25524052)

  • 1. Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.
    Cohen-Barak O; Wildeman J; van de Wetering J; Hettinga J; Schuilenga-Hut P; Gross A; Clark S; Bassan M; Gilgun-Sherki Y; Mendzelevski B; Spiegelstein O
    J Clin Pharmacol; 2015 May; 55(5):573-83. PubMed ID: 25524052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TV-1380 attenuates cocaine-induced changes in cardiodynamic parameters in monkeys and reduces the formation of cocaethylene.
    Shemesh-Darvish L; Shinar D; Hallak H; Gross A; Rosenstock M
    Drug Alcohol Depend; 2018 Jul; 188():295-303. PubMed ID: 29807217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.
    Gilgun-Sherki Y; Eliaz RE; McCann DJ; Loupe PS; Eyal E; Blatt K; Cohen-Barak O; Hallak H; Chiang N; Gyaw S
    Drug Alcohol Depend; 2016 Sep; 166():13-20. PubMed ID: 27394932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reengineering of Albumin-Fused Cocaine Hydrolase CocH1 (TV-1380) to Prolong Its Biological Half-Life.
    Cai Y; Zhou S; Jin Z; Wei H; Shang L; Deng J; Zhan CG; Zheng F
    AAPS J; 2019 Nov; 22(1):5. PubMed ID: 31754920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.
    Shram MJ; Cohen-Barak O; Chakraborty B; Bassan M; Schoedel KA; Hallak H; Eyal E; Weiss S; Gilgun-Serki Y; Sellers EM; Faulknor J; Spiegelstein O
    J Clin Psychopharmacol; 2015 Aug; 35(4):396-405. PubMed ID: 26082975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys.
    Schindler CW; Justinova Z; Lafleur D; Woods D; Roschke V; Hallak H; Sklair-Tavron L; Redhi GH; Yasar S; Bergman J; Goldberg SR
    Addict Biol; 2013 Jan; 18(1):30-9. PubMed ID: 22264200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties.
    Gao Y; LaFleur D; Shah R; Zhao Q; Singh M; Brimijoin S
    Chem Biol Interact; 2008 Sep; 175(1-3):83-7. PubMed ID: 18514640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV-1106, a Long-Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects.
    Cohen-Barak O; Barkay H; Rasamoelisolo M; Butler K; Yamada K; Bassan M; Yoon E; Spiegelstein O
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):331-342. PubMed ID: 27489211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butyrylcholinesterase accelerates cocaine metabolism: in vitro and in vivo effects in nonhuman primates and humans.
    Carmona GN; Jufer RA; Goldberg SR; Gorelick DA; Greig NH; Yu QS; Cone EJ; Schindler CW
    Drug Metab Dispos; 2000 Mar; 28(3):367-71. PubMed ID: 10681384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Highly Efficient Long-Acting Cocaine Hydrolase Entity to Accelerate Cocaine Metabolism.
    Zheng F; Jin Z; Deng J; Chen X; Zheng X; Wang G; Kim K; Shang L; Zhou Z; Zhan CG
    Bioconjug Chem; 2022 Jul; 33(7):1340-1349. PubMed ID: 35767675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats.
    Carmona GN; Schindler CW; Greig NH; Holloway HW; Jufer RA; Cone EJ; Gorelick DA
    Eur J Pharmacol; 2005 Jul; 517(3):186-90. PubMed ID: 15967428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy.
    Gorelick DA
    Drug Alcohol Depend; 1997 Dec; 48(3):159-65. PubMed ID: 9449014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
    Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase.
    Sun H; Shen ML; Pang YP; Lockridge O; Brimijoin S
    J Pharmacol Exp Ther; 2002 Aug; 302(2):710-6. PubMed ID: 12130735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
    Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
    Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice.
    Murthy V; Gao Y; Geng L; LeBrasseur NK; White TA; Parks RJ; Brimijoin S
    Vaccine; 2014 Jul; 32(33):4155-62. PubMed ID: 24892251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase.
    Carmona GN; Schindler CW; Shoaib M; Jufer R; Cone EJ; Goldberg SR; Greig NH; Yu QS; Gorelick DA
    Exp Clin Psychopharmacol; 1998 Aug; 6(3):274-9. PubMed ID: 9725111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity.
    Duysen EG; Bartels CF; Lockridge O
    J Pharmacol Exp Ther; 2002 Aug; 302(2):751-8. PubMed ID: 12130740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.